PMID: 225 WanXZhangYWanYXiongMXieALiangYet al
this difference may result from a ~5x stronger effect produced by GLP-1 analogs, compared to DPP-4 inhibitors (Charbonnel & Cariou, 2011) No change in weight Contraindications: type I diabetes (these patients lack pancreatic beta cells) diabetic ketoacidosis (it would not be effective for treating this condition) an association between DPP-4 inhibitors and heart failure has been observed for two members of this drug class in patients with type 2 DM and atherosclerosis
Instead, what I believe we are seeing is a larger change in cultural drivers including (and, maybe primarily) a desire for a healthier lifestyle. Smith, when acknowledging that he sold off his Diageo stakes, predicted that consumers will be drinking less , but better
Precision at every step is what separates landmark studies from forgotten data sets
Complex I deficiency in Parkinson's disease frontal cortex
A whopping 94% feel that GLP-1s will negatively impact disadvantaged groups, who have less access to these drugs